Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib in Early-Stage TNBC
NCT05112536Phase 2Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in triple-negative breast cancer (TNBC), sponsored by G1 Therapeutics, Inc. Primary endpoint: Immune-based Mechanism of Action. Started Mar 2022; status: completed.
02
Drugs
trilaciclib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05112536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112536.